These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17505827)

  • 1. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
    Britten CD; Kabbinavar F; Hecht JR; Bello CL; Li J; Baum C; Slamon D
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):515-24. PubMed ID: 17505827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
    Houk BE; Bello CL; Poland B; Rosen LS; Demetri GD; Motzer RJ
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):357-71. PubMed ID: 19967539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.
    Shirao K; Nishida T; Doi T; Komatsu Y; Muro K; Li Y; Ueda E; Ohtsu A
    Invest New Drugs; 2010 Dec; 28(6):866-75. PubMed ID: 19730791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
    Leong S; Eckhardt SG; Chan E; Messersmith WA; Spratlin J; Camidge DR; Diab S; Khosravan R; Lin X; Chow Maneval E; Lockhart AC
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):65-74. PubMed ID: 22623210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
    Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
    Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
    Makino K; Yoda K; Tomoishi J; Kume H
    BMC Res Notes; 2014 Dec; 7():872. PubMed ID: 25471941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
    Dubois SG; Shusterman S; Ingle AM; Ahern CH; Reid JM; Wu B; Baruchel S; Glade-Bender J; Ivy P; Grier HE; Adamson PC; Blaney SM
    Clin Cancer Res; 2011 Aug; 17(15):5113-22. PubMed ID: 21690570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor.
    Khosravan R; Motzer RJ; Fumagalli E; Rini BI
    Clin Pharmacokinet; 2016 Oct; 55(10):1251-1269. PubMed ID: 27154065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
    Faivre S; Delbaldo C; Vera K; Robert C; Lozahic S; Lassau N; Bello C; Deprimo S; Brega N; Massimini G; Armand JP; Scigalla P; Raymond E
    J Clin Oncol; 2006 Jan; 24(1):25-35. PubMed ID: 16314617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Burstein HJ; Elias AD; Rugo HS; Cobleigh MA; Wolff AC; Eisenberg PD; Lehman M; Adams BJ; Bello CL; DePrimo SE; Baum CM; Miller KD
    J Clin Oncol; 2008 Apr; 26(11):1810-6. PubMed ID: 18347007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
    Robert F; Sandler A; Schiller JH; Liu G; Harper K; Verkh L; Huang X; Ilagan J; Tye L; Chao R; Traynor AM
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):669-80. PubMed ID: 20043166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
    Choong NW; Kozloff M; Taber D; Hu HS; Wade J; Ivy P; Karrison TG; Dekker A; Vokes EE; Cohen EE
    Invest New Drugs; 2010 Oct; 28(5):677-83. PubMed ID: 19649772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
    Bang YJ; Kang YK; Kang WK; Boku N; Chung HC; Chen JS; Doi T; Sun Y; Shen L; Qin S; Ng WT; Tursi JM; Lechuga MJ; Lu DR; Ruiz-Garcia A; Sobrero A
    Invest New Drugs; 2011 Dec; 29(6):1449-58. PubMed ID: 20461441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.
    Fountzilas G; Fragkoulidi A; Kalogera-Fountzila A; Nikolaidou M; Bobos M; Calderaro J; Andreiuolo F; Marselos M
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):649-60. PubMed ID: 19655144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
    Houk BE; Bello CL; Kang D; Amantea M
    Clin Cancer Res; 2009 Apr; 15(7):2497-506. PubMed ID: 19258444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study.
    DuBois SG; Shusterman S; Reid JM; Ingle AM; Ahern CH; Baruchel S; Glade-Bender J; Ivy P; Adamson PC; Blaney SM
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1021-7. PubMed ID: 22179104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
    Papaetis GS; Syrigos KN
    BioDrugs; 2009; 23(6):377-89. PubMed ID: 19894779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.
    Theou-Anton N; Faivre S; Dreyer C; Raymond E
    Drug Saf; 2009; 32(9):717-34. PubMed ID: 19670913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.